Wells Fargo lowered the firm’s price target on Morphic to $64 from $67 and keeps an Overweight rating on the shares. The firm expects 2024 to be a quieter year in terms of news and data flow, but still believes MORF-057 is de-risked in ulcerative colitis, the analyst tells investors in a research note. Wells sees shares trading up later this year into the 1H25 Phase 2b read out.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MORF: